Management of peripheral neuropathy caused by microtubule inhibitors

Area of Science:

• Oncology Nursing
• Neuroscience
• Pharmacology

Background:

• Chemotherapy agents targeting microtubules, such as taxanes and vinca alkaloids, can cause peripheral neuropathy.
• Peripheral neuropathy presents a significant risk for patients undergoing cancer treatment.
• Risk factors include the specific chemotherapeutic regimen, patient history, and comorbidities.

Purpose of the Study:

• To provide nurses with tools and strategies for managing chemotherapy-induced peripheral neuropathy (CIPN).
• To emphasize the importance of early identification and patient education in mitigating CIPN.
• To enhance nurses' role in improving patient quality of life during cancer therapy.

Main Methods:

• Review of clinical presentations of peripheral neuropathy.
• Discussion of various clinical assessment tools for neuropathy (grading scales, questionnaires, quantitative sensory testing, psychometric assessments).
• Analysis of management strategies including dose modification and supportive care.

Main Results:

• Peripheral neuropathy typically manifests as sensory loss, numbness, or tingling, starting distally and progressing proximally.
• No specific agents effectively prevent or treat severe neuropathy; management relies on vigilant monitoring and intervention.
• Dose reduction or treatment delay may be necessary for moderate to severe neuropathy.

Conclusions:

• Nurses play a crucial role in managing peripheral neuropathy through early detection and patient education.
• Effective management can significantly impact treatment efficacy and patient quality of life.
• Proactive nursing interventions are key to mitigating the adverse effects of chemotherapy-induced peripheral neuropathy.